TCBP | TC Biopharm (Holdings) Plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.60 - 7.30
52 Week Range	2.1100 - 1,140.00
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	312,216
Average Volume	182,271
Shares Outstanding	295,212
Market Cap	2,090,101
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-02-11

Valuation
Profitability
Growth
Health
P/E Ratio	-0.04
Forward P/E Ratio	N/A
EPS	-198.18
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	41
Country	UK
Website	TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TCBP's peers: APCX, ZVSA, PALI, UNCY, APGN, IMMX, REVB, ZURA, PHIO, RNAZ, ICU, VIRI, SONN, QNRX, ALLR, KRBP, VRAX, BDRX, BWV, PXMD, HILS, GGROW

*Chart delayed

Analyzing fundamentals for TCBP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see TCBP Fundamentals page.

Watching at TCBP technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on TCBP Technicals page.